Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Sanchez Alberti, AndrésBivona, Augusto E
Cerny, Natacha
Schulze, Kai
Weißmann, Sebastian
Ebensen, Thomas
Morales, Celina
Padilla, Angel M
Cazorla, Silvia I
Tarleton, Rick L
Guzmán, Carlos A
Malchiodi, Emilio L
Issue Date
2017
Metadata
Show full item recordAbstract
The parasite Trypanosoma cruzi is the causative agent of Chagas disease, a potentially life-threatening infection that represents a major health problem in Latin America. Several characteristics of this protozoan contribute to the lack of an effective vaccine, among them: its silent invasion mechanism, T. cruzi antigen redundancy and immunodominance without protection. Taking into account these issues, we engineered Traspain, a chimeric antigen tailored to present a multivalent display of domains from key parasitic molecules, combined with stimulation of the STING pathway by c-di-AMP as a novel prophylactic strategy. This formulation proved to be effective for the priming of functional humoral responses and pathogen-specific CD8+ and CD4+ T cells, compatible with a Th1/Th17 bias. Interestingly, vaccine effectiveness assessed across the course of infection, showed a reduction in parasite load and chronic inflammation in different proof of concept assays. In conclusion, this approach represents a promising tool against parasitic chronic infections.Citation
Engineered trivalent immunogen adjuvanted with a STING agonist confers protection against Trypanosoma cruzi infection. 2017, 2:9 NPJ VaccinesAffiliation
Helmholtz-Zentrum für Infektionsforschung GmbH, Inhoffenstr. 7, 38124 Braunschweig, Germany.Journal
NPJ vaccinesPubMed ID
29263868Type
ArticleLanguage
enISSN
2059-0105ae974a485f413a2113503eed53cd6c53
10.1038/s41541-017-0010-z
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
Related articles
- Mucosal Heterologous Prime/Boost Vaccination Induces Polyfunctional Systemic Immunity, Improving Protection Against Trypanosoma cruzi.
- Authors: Sanchez Alberti A, Bivona AE, Matos MN, Cerny N, Schulze K, Weißmann S, Ebensen T, González G, Morales C, Cardoso AC, Cazorla SI, Guzmán CA, Malchiodi EL
- Issue date: 2020
- Heterologous Chimeric Construct Comprising a Modified Bacterial Superantigen and a Cruzipain Domain Confers Protection Against Trypanosoma cruzi Infection.
- Authors: Antonoglou MB, Sánchez Alberti A, Redolfi DM, Bivona AE, Fernández Lynch MJ, Noli Truant S, Sarratea MB, Iannantuono López LV, Malchiodi EL, Fernández MM
- Issue date: 2020
- Immunization with Tc52 or its amino terminal domain adjuvanted with c-di-AMP induces Th17+Th1 specific immune responses and confers protection against Trypanosoma cruzi.
- Authors: Matos MN, Cazorla SI, Schulze K, Ebensen T, Guzmán CA, Malchiodi EL
- Issue date: 2017 Feb
- Nasal immunization with a L. lactis-derived trans-sialidase antigen plus c-di-AMP protects against acute oral T. cruzi infection.
- Authors: Pacini MF, González FB, Dinatale B, Bulfoni Balbi C, Villar SR, Farré C, Lupi G, Espariz M, Blancato VS, Magni C, Marcipar I, Pérez AR
- Issue date: 2022 Apr 1
- Intranasal trans-sialidase-based vaccine against Trypanosoma cruzi triggers a mixed cytokine profile in the nasopharynx-associated lymphoid tissue and confers local and systemic immunogenicity.
- Authors: Pacini MF, Balbi CB, Dinatale B, González FB, Prochetto E, De Hernández MA, Cribb P, Farré C, Espariz M, Blancato VS, Magni C, Marcipar I, Pérez AR
- Issue date: 2023 May